Market News Latest

Alzheimer’s Disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Alzheimer’s Disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

November 17
04:04 2021
Alzheimer’s Disease Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s, “Alzheimer’s Disease (AD) – Pipeline Insights, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease (AD) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s “Alzheimer’s Disease Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Alzheimer’s Disease pipeline landscapes. 

The report comprises Alzheimer’s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Alzheimer’s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Alzheimer’s Disease pipeline products.     

Alzheimer’s Disease Overview

Alzheimer’s disease is a debilitating neurological disorder that gradually erodes memory and cognitive abilities, as well as the ability to perform even the most basic tasks. Alzheimer’s patients have difficulty doing simple tasks such as driving a car, preparing a meal, or paying bills. They can repeatedly ask the same questions, become easily disoriented, accidentally drop or misplace objects, and find even simple things perplexing. Some people become worried, frustrated, or aggressive as the disease progresses.

•Alzheimer’s disease is a disease whose precise causes are unknown. However, at a fundamental stage, brain proteins malfunction, disrupting the work of brain cells (neurons) and triggering a cascade of toxic events. Neurons become weakened, lose their ties, and ultimately die.

Some of the key takeaways from the Alzheimer’s Disease Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Eisai/ BioArctic AB, Biogen, Hoffmann-La Roche, Cortexyme, Otsuka Pharmaceutical, etc., are developing therapies for the treatment of Alzheimer’s Disease.

  • Emerging therapies such as Lecanemab (BAN2401), Aducanumab (BIIB037), Gantenerumab, Atuzaginstat (COR388), Brexpiprazole, are expected to have a significant impact on the  Alzheimer’s Disease market in the coming years.

Get an overview of pipeline landscape @ Alzheimer’s Disease Clinical Trials Analysis 

Alzheimer’s Disease Pipeline Therapies along with Key Players:

  • Lecanemab (BAN2401): Eisai/BioArctic AB

  • Aducanumab (BIIB037): Biogen 

  • Gantenerumab: Hoffmann-La Roche

  • Atuzaginstat (COR388): Cortexyme 

  • Brexpiprazole: Otsuka Pharmaceutical

Scope of Alzheimer’s Disease Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Eisai/ BioArctic AB, Biogen, Hoffmann-La Roche, Cortexyme, Otsuka Pharmaceutical, and others.

  • Pipeline Therapies:  Lecanemab (BAN2401), Aducanumab (BIIB037), Gantenerumab, Atuzaginstat (COR388), Brexpiprazole, and others.

Table of Contents

1

Alzheimer’s Disease Report Introduction

2

Alzheimer’s Disease Executive Summary

3

Alzheimer’s Disease Overview

4

Alzheimer’s Disease- Analytical Perspective In-depth Commercial Assessment

5

Alzheimer’s Disease Pipeline Therapeutics

6

Alzheimer’s Disease Late Stage Products (Phase II/III)

7

Alzheimer’s Disease Mid Stage Products (Phase II)

8

Alzheimer’s Disease Early Stage Products (Phase I)

9

Alzheimer’s Disease Preclinical Stage Products

10

Alzheimer’s Disease Therapeutics Assessment

11

Alzheimer’s Disease Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Alzheimer’s Disease Key Companies

14

Alzheimer’s Disease Key Products

15

Alzheimer’s Disease Unmet Needs

16 

Alzheimer’s Disease Market Drivers and Barriers

17

Alzheimer’s Disease Future Perspectives and Conclusion

18

Alzheimer’s Disease Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Alzheimer’s Disease Drugs Pipeline Report.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/